Chairman and Chief Executive Officer
Dwight Babcock joins IsoRay as Chairman and Chief Executive Officer after having served as a director of the company. Mr. Babcock has over 30 years experience as a CEO. Prior to coming to IsoRay Mr. Babcock has served as Chairman and Chief Executive Officer of Apex Data Systems, Inc., an information technology company, since 1975. Apex Data Systems automates the administration and claims adjudication needs of insurance companies both nationally and internationally. Mr. Babcock was formerly President and CEO of Babcock Insurance Corporation (BIC) from 1974 until 1985. BIC was a nationally recognized third party administrator operating within 35 states. Mr. Babcock has knowledge and experience in the equity arena and has participated in various activities within the venture capital, private and institutional capital markets. Mr. Babcock studied marketing and economics at the University of Arizona where he currently serves on the University of Arizona Astronomy Board.
Vice President–Quality Assurance/Regulatory Affairs
Mr. Swindler joined IsoRay in 2006, bringing nearly four decades of experience in the medical device and pharmaceutical industries. He worked extensively in the areas of FDA and ISO/MDD regulatory compliance, quality systems, offshore manufacturing, start-up and project management. He was most recently vice-president of QA/RA for Seattle-based Medisystems Corporation, a $100 million manufacturer and importer of dialysis disposables. He has held similar positions with Marquest Medical Products, Sherwood Medical Products, a division of American Home Products Corporation, and Mead Johnson & Company, a division of Bristol-Meyers Squibb.
Mr. Swindler has a B.S. in biomedical engineering from Rose Hulman Institute of Technology and an M.B.A. from the University of Evansville.
William A. Cavanagh
Vice President, Research and Development
William Cavanagh began his extensive career in cancer treatment technologies in the early 1990s, when he helped head research and development of a therapy involving the insertion of radioactive sources directly into the prostate for the treatment of prostate cancer (prostate brachytherapy). He has designed several cancer treatment-related studies, is listed as an author on 34 peer-reviewed publications, and is the listed inventor on a U.S. patent application detailing a novel treatment for cancer.
Mr. Cavanagh has also served as Director of the Haakon Ragde Foundation for Advanced Cancer Studies in Seattle, Washington, where he lead the research foundation in the selection of viable research projects directed at treating advanced cancers.
With more than 40 years experience in the radiochemistry field, Mr. Bray was a founder of IsoRay and leads development of the company’s innovative processes.
Mr. Bray is recognized nationally and internationally as a technical expert in separations, recovery and purification of isotopes and is a noted authority in the use of cesium and strontium ion exchange. In 2000, Mr. Bray received the “Radiation Science and Technology” award from the American Nuclear Society and has authored or co-authored more than 110 research publications and 12 articles for 9 technical books. He holds 24 U.S. and foreign patents.
He holds a B.A. in chemistry from Lake Forest College.